At the ISPOR Europe 2024 Conference today, CapeStart, Inc. debuted MadeAi™—a generative AI-based platform that dramatically streamlines the synthesis of clinical information—with its first solut...
MadeAi’s first solution, MadeAi-LR—developed in collaboration with leading pharma manufacturers—makes literature review 40% faster, delivering 90% accuracy
BARCELONA, Spain & CAMBRIDGE, Mass.: At the ISPOR Europe 2024 Conference today, CapeStart, Inc. debuted MadeAi™—a generative AI-based platform that dramatically streamlines the synthesis of clinical information—with its first solution, MadeAi-LR. Supporting literature review, MadeAi-LR unlocks efficiency for systematic literature reviews (SLRs), clinical evidence reports (CERs), meta research, targeted literature reviews (TLRs), and other clinical literature assessments.
For decades, the traditional approach to literature review has involved onerous, manual, time-consuming research tasks that divert professionals from higher-value tasks. When optimized by CapeStart’s AI experts, MadeAi-LR cuts literature review time nearly in half—with 90% accuracy for title and abstract screening, and more than 80% accuracy for data extraction, and single- and multiple-article summarizations.
Offering centralization and process transparency for users, MadeAi-LR was built in partnership with top 20 pharmaceutical manufacturers where it is freeing up their teams to focus on more complex work, while enabling increased productivity, more rigorously prepared regulatory submissions, better-informed internal strategies, and more thorough research for publications. With a single literature review requiring hundreds of hours to complete, MadeAi-LR is helping leading pharma, biotech, and medical device companies to save time, optimize in-demand resources, and scale research to drive innovation.
“PhD researchers and highly credentialed life science experts should spend their time on achieving breakthroughs in health, not consumed by mundane tasks that can be offloaded at high accuracy to the right GenAI technology,” said Gaugarin Oliver, founder and CEO of CapeStart. “Users of MadeAi-LR are performing more literature reviews in less time, removing the roadblocks to rapid growth and scalability and obtaining an immediate return-on-investment in time and resources. CapeStart remains hyper-focused on continually improving the MadeAi platform and bringing more value to life science innovation.”
GenAI-powered, Expert Verified
MadeAi, the underlying GenAI-enabled platform for MadeAi-LR, provides the foundation for CapeStart’s AI services and customer solutions. Additional MadeAi offerings will include support for pharmacovigilance, clinical content generation, and global value dossier development, among others.
Harnessing nearly a decade of developed AI knowledge and expertise, clinical understanding, and life science experience from custom consulting work, MadeAi-LR’s framework ensures compliance with FDA and EMA requirements for SLR submissions. Additionally, the platform provides a central repository that gives stakeholders visibility and access to each workflow step, along with transparency on considerations for included and excluded material. Supported by a human-in-the-loop (HITL) approach that enhances AI innovation coupled with expert validation, MadeAi-LR turns a burdensome task into a streamlined, highly accurate source of added productivity.
Making Literature Review an Engine of Productivity
A rich feature set in MadeAi-LR allows teams to focus less time on literature review work and more time on higher-order thinking:
MadeAi-LR is the recent winner of a Stevie® award in the 21st Annual International Business Awards® program, where it was recognized as an innovative Artificial Intelligence/Machine Learning Solution in Healthcare within the Business Technology category.
For more information visit CapeStart at ISPOR 2024, booth #329, or visit www.capestart.com.
About CapeStart
CapeStart helps organizations compete and win in the AI economy. Its AI solutions, including a GenAI-enabled life science platform, bring the efficiency of AI to life science firms, while maintaining essential human oversight. CapeStart’s skilled data experts and software developers provide complex data annotation, ML and AI model development, and software development services to healthcare, finance, and retail companies, among others. Based in Cambridge, MA, CapeStart serves 100+ clients with 600+ resources across North America, the Middle East, and Asia. For more visit www.capestart.com.
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Mutual of Omaha is excited to announce its relationship with Workday, Inc. to help employer-provided insurance customers improve their benefits programs…
Sei Labs, the main contributor to Sei, the fastest Layer 1 EVM blockchain, today announced its latest roadmap, dubbed “Giga”, charting its path to becoming…
PM360's 13th Annual Innovations Issue recognizes Swoop for its cutting-edge contributions to data-driven healthcare marketing. Honored with three prestigious…
Mastercard (NYSE: MA) today completed its acquisition of Recorded Future. “As the world becomes more digitized, there's an increased focus on securing…